5-羟色胺2A受体基因T102C多态性和多巴胺D3受体基因Ser9Gly多态性能否预测急性加重期精神分裂症患者的临床改善情况？来自利培酮自然治疗反应的结果。

Could HTR2A T102C and DRD3 Ser9Gly predict clinical improvement in patients with acutely exacerbated schizophrenia? Results from treatment responses to risperidone in a naturalistic setting.

作者信息

Kim Byungsu, Choi Eui Yul, Kim Chang Yoon, Song Kyuyung, Joo Yeon Ho

机构信息

Department of Psychiatry, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.

出版信息

Hum Psychopharmacol. 2008 Jan;23(1):61-7. doi: 10.1002/hup.897.

DOI:10.1002/hup.897

PMID:17924589

Abstract

OBJECTIVE

This study seeks to replicate previous results indicating that T102C in the serotonin 2A receptor (HTR2A) and Ser9Gly in the dopamine D3 receptor (DRD3) were associated with a risperidone response to acutely exacerbated schizophrenia, and to determine whether possession of these alleles predicts clinical improvement in a naturalistic setting.

METHODS

We consecutively recruited 100 schizophrenia patients and assessed clinical improvement after 4 weeks of risperidone treatment.

RESULTS

The patients with T/T in the HTR2A gene showed less clinical improvement than did those with T/C or C/C (p = 0.044). In the case of the DRD3 gene, we did not find statically significant association with clinical improvement (p = 0.061). When patients were categorized into responders and nonresponders, the C allele was more frequent in responders (OR = 2.28, 95%CI = 1.06-4.91, p = 0.039). When combinations of the two polymorphisms were considered, patients who had T/T in the HTR2A gene and encoded Ser/Ser or Ser/Gly from DRD3 gene had a higher propensity to non-responsiveness compared to other subjects (OR = 3.57, 95%CI = 1.10-11.62, p = 0.039).

CONCLUSIONS

Our findings suggest that the HTR2A T102C could be a potential indicator of clinical improvement after risperidone treatment.

摘要

目的

本研究旨在重复先前的结果，即血清素2A受体（HTR2A）中的T102C和多巴胺D3受体（DRD3）中的Ser9Gly与急性加重型精神分裂症对利培酮的反应相关，并确定拥有这些等位基因是否能预测在自然环境中的临床改善情况。

方法

我们连续招募了100名精神分裂症患者，并在利培酮治疗4周后评估临床改善情况。

结果

HTR2A基因中T/T型患者的临床改善程度低于T/C型或C/C型患者（p = 0.044）。对于DRD3基因，我们未发现其与临床改善有统计学意义的关联（p = 0.061）。当将患者分为反应者和无反应者时，反应者中C等位基因更为常见（OR = 2.28，95%CI = 1.06 - 4.91，p = 0.039）。当考虑两种多态性的组合时，与其他受试者相比，HTR2A基因中为T/T且DRD3基因编码Ser/Ser或Ser/Gly的患者无反应倾向更高（OR = 3.57，95%CI = 1.10 - 11.62，p = 0.039）。